Anaplastic large cell lymphoma (ALCL) is a distinct subtype of non-Hodgkin's lymphoma. Most of ALCLs (85%) carry a chromosomal translocation involving different partners in the 5 0 portion, and the anaplastic lymphoma kinase (ALK) receptor kinase domain in the 3 0 portion. These translocations induce the ectopic expression of X-ALK proteins, thought to be involved in lymphomagenesis, through the dysregulation of cell proliferation and apoptotic pathways. In the present study, based on several ALK þ and ALK À ALCL cell lines and biopsy specimens, we showed that serpin A1, a secretory glycoprotein, was overexpressed in ALK þ ALCL cell lines and ALK þ tumors at both the transcriptional and translational levels. The crucial role of NPM-ALK in the regulation of serpin A1 expression was further demonstrated by using both ectopic expression and downregulation, by RNA interference, of the NPM-ALK oncogene. In addition, in ALK þ tumors, serpin A1 expression appeared to be correlated with the clinical status of the patients as the serpin A1 mRNA level was higher in patients presenting with extranodal dissemination. These data, together with the pattern of expression of serpin A1 we observed in ALK þ tumors, suggest that serpin A1 has an invasion-promoting effect in ALK þ ALCL.
Introduction
Anaplastic large cell lymphoma (ALCL) is a distinct type of nonHodgkin's lymphoma of T/null cell phenotype that is positive for CD30. 1 Majority of ALCLs (70%) carries the t(2;5)(p23;q35) or variant translocations (15%) involving the 2p23 locus, resulting in the overexpression of the tyrosine kinase receptor anaplastic lymphoma kinase (ALK). 2 The t(2;5) translocation creates the NPM-ALK fusion gene, whereas other abnormalities create a variety of other X-ALK fusion genes. 2, 3 ALK is currently thought to be directly involved in lymphomagenesis through its interaction with members of multiple signaling pathways, resulting in the dysregulation of both cell proliferation and apoptosis. 4 A number of clinical entities have been recognized within the group of lymphomas known as ALCLs. 1, 5 Primary systemic ALCLs involve lymph nodes and extranodal sites including skin, bone, soft tissue, lung, testis, and liver, in approximately 30% of cases. Most systemic ALCLs occurring in children and young adults are ALK þ , whereas ALCLs occurring in elderly patients are often ALK À . 5 Systemic ALK À ALCLs tend to be more aggressive than ALK þ ALCLs. 6, 7 ALK þ systemic ALCLs are highly chemosensitive with complete remission rates ranging from 60 to 100%. However, 20-40% of the patients relapse. 8, 9 Serpin A1 is a secretory glycoprotein, synthesized primarily in the liver, but also in extra-hepatic tissues and cells, including monocytes and tumor cells. Interest has focused on serpin A1 as its genetic homozygous deficiency is associated with the development of emphysema and chronic liver disease. Serpin A1 plays an important role in the control of the inflammatory response by inhibiting the excess of leukocyte elastase, which is its physiologic target. 10 The prognostic significance of serpin A1 expression has been studied mainly in various adenocarcinomas. [11] [12] [13] In colorectal and lung adenocarcinomas, the level of serpin A1 expression is related to the invasive and metastatic capacity of tumor cells. 13, 14 Clinical studies of patients with gastric and lung adenocarcinoma showed that strongly serpin A1-positive cases have poorer prognosis than weakly to moderately serpin A1-positive or serpin A1-negative cases. 11, 12 In a previous study using the suppression subtractive hybridization (SSH) technique to compare the gene expression between an ALK þ ALCL cell line and a clinical case of ALK À ALCL, we found that the serpin A1 gene was overexpressed in the ALK þ ALCL cell line. 15 This result prompted us to further investigate serpin A1 expression at both the transcriptional and translational levels in ALK þ and ALK À cell lines and biopsy specimens from patients with systemic ALCLs. In the present study, based on several ALCL cell lines (four ALK þ and one ALK À ) and biopsy specimens from patients presenting with systemic ALCL (n ¼ 63), we showed that serpin A1 was overexpressed in ALK þ ALCL cell lines and ALK þ tumors at both the transcriptional and translational levels. The crucial role of NPM-ALK in the regulation of serpin A1 expression was further demonstrated using both ectopic expression and specific downregulation of the NPM-ALK oncogene in NIH3T3 cells and COST cells, respectively. Actually, using RNA interference experiments in the human ALK þ COST cell line, we showed that the decrease of ALK expression was correlated with a proportional diminution of serpin A1 expression. In addition, in ALK þ tumors, serpin A1 expression appeared to be correlated with the clinical status of the patients, as the serpin A1 mRNA level was higher in patients presenting with extranodal dissemination.
Materials and methods

Material
Cell lines. Four ALK þ ALCL cell lines were studied: Karpas 299, 16 SU-DHL-1, 17 PIO (generated in the laboratory, unpub-lished data), established from common type ALCLs and the COST cell line, established in the laboratory from a small cell variant ALCL. 18 FEPD was the only ALK À ALCL cell line studied and was also established from a common type ALCL. 19 These cells were maintained in culture as previously described. 20 The NIH3T3 cell line stably transfected with an empty vector (NIH3T3-Neo) or a vector expressing the NPM-ALK oncogene (NIH3T3-NPM-ALK) was maintained in culture as previously described. 21 Biopsy specimens. Only primary systemic adult and pediatric ALCLs were included in this study ('Groupe d'Etude des Lymphomes de l'Adulte' and 'Société Française de lutte contre les Cancers de l'Enfant et de l'adolescent'). The diagnosis of ALCL was based on morphological criteria, as described by the WHO classification. 1 Tumor cells co-expressed CD30 and EMA antigens. Frozen diagnostic tumor specimens from 32 patients with systemic ALCL with patient informed consent were studied: lymph node (29 cases), skin (two cases) and soft tumor mass (one case). Twenty-five cases were ALK1 þ and seven cases were ALK1
À . 22 Formalin-fixed and paraffin-embedded blocks were available for only 15 of these cases (11 ALK1 þ , four ALK1 À ). The 17 remaining cases were Bouin's fixed biopsies not suitable for serpin A1 immunohistochemistry. The median follow-up was 38.5 months. Of the 25 ALK þ patients, one died before staging, 11 presented with nodal involvement only, whereas 13 had extranodal dissemination. In the latter group, bone marrow involvement was not taken into account because it has already been shown that it did not bear any impact on prognosis in a multivariate analysis. 8 Thirty-one additional cases (26 ALK þ , five ALK À ), with only formalin-fixed and paraffinembedded blocks, were retrieved from our tissue bank (Department of Pathology, CHU Purpan, Toulouse, France).
Methods
RNA extraction. Total RNAs were extracted from 10 Â 10 6 cells or from 40 Â 5 mm frozen sections using the 'Total SV RNA isolation kit' (Promega, Charbonnières, France).
Home-made cDNA macroarray. Based on our previous study using the SSH technique, 15 we designed a nylon macroarray by selecting 200 genes, including serpin A1. Array conception and hybridizations were performed as previously described. 23 Signal quantification was carried out using XDotsReader (COSE, Linux) and data were analyzed using the Bioplot software designed by Serguei Sokol at the Toulouse Genopô le (https://bio71.gba.insa-tlse.fr/). Statistical significance of the observed differences was assessed by Student's t-test.
Affymetrix microarrays. The present study benefited from the results obtained in a separate study aimed at analyzing the molecular signature of ALCLs (manuscript in preparation). The Affymetrix GeneChipTM Human Genome U133A oligonucleotide array, used to establish the gene expression signature of the 32 frozen biopsies of ALCL, included three serpin A1 probe sets (202833_s_at; 211428_at; 211429_s_at). The probe synthesis and hybridizations were performed according to standard Affymetrix protocols at the Strasbourg Génopô le (Strasbourg, France). Raw feature data were normalized using the RMA (Robust Multichip Average) method 24 (package affy v1.4.32). Genes that were differentially expressed between ALK þ and ALK À ALCL were identified through using univariate t-tests with BRB ArrayTools software (v3.2.0 beta 5). This calculus yielded a P-value for each of the 19 787 probe sets. Probe sets having a P-value below a given threshold (0.001) were selected. To evaluate the number of false positives in this selection (owing to multiple testing), we used a Monte-Carlo approach (implemented in BRB comparison tool 25 ) based on 1000 random permutations of the label of the samples. Having ordered the list of probe sets by P-value, this method evaluates the rank n for which the False Discovery Rate is lower than a chosen percentage (with a probability of 90%), where 'false discovery' is relative to the chosen level of significance for the univariate test. This method also evaluates the rank n' for which the Number of False Discoveries is less then a chosen number (with a probability of 90%).
Northern blot. Northern blot analysis was performed using standard techniques. The Serpin A1 mRNA level was normalized to the P0 mRNA level, a housekeeping gene coding a Ribosomal Phosphoprotein. Statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego, CA, USA). One-way analysis of variance (ANOVA) was performed to detect differences in mRNA levels between cell lines. Bonferroni post-test was used for pair comparisons if the overall difference was significant. A P-value lower than 5% was considered significant.
Quantitative reverse transcription-polymerase chain reaction. For each cell line, cDNA from five independent total RNA extractions were synthesized from 2 mg of total RNA, using Superscript II s reverse transcriptase (Invitrogen, Cergy Pontoise, France) with random hexamers as primers. cDNA were first reverse transcribed, diluted (1:10), and quantitative real-time polymerase chain reaction was then performed with an ABI PRISM 7000 sequence detection system (Applied Biosystems, Courtaboeuf, France) using SYBR green Premix (SYBR Green Jumpstart Taq Ready Mix, Sigma, France), with initial denaturation at 501C for 2 min and 951C for 10 min followed by 40 cycles of 15 s at 951C and 1 min at 601C, and duplicate C t values were obtained. MLN51 and c-Raf1 were used as reference genes. All primers (listed in Table 1 ) were used at 300 nM. PCR product specificity was evaluated by generating a dissociation curve. The presented data correspond to DC t ¼ C ttarget gene À geometric mean of C t reference genes . Statistical analyses were performed as for the Northern blot.
RNA interference and cell transfection. COST cells (2 Â 10 6 ) were resuspended in 100 ml of V solution from Amaxa Biosystem (Koeln, Germany) and 200 nM of ALK siRNA duplex (5 0 -UAUGAAGGAGGUACCUCUG-3 0 ) or negative control siR-NA duplex designed and purchased from Eurogentec (Angers, Table 1 Primers used for RT-qPCR Name Sequence Serpin A1 expression correlates with clinical status in ALK þ ALCL MM Duplantier et al France). Cell suspensions were then submitted to the nucleofection program A30 according to the Amaxa protocol for cell suspension using the Amaxa Nucleofector apparatus. Cells were then transferred into 12-well plates containing 2 ml of Iscove þ 15% decomplemented fetal calf serum (FCS).
Western blot. Western blot analysis was performed as previously described. 21 Monoclonal actin antibody (clone AC-15, diluted at 1:20 000) was from Sigma (Lyon, France). Polyclonal anti-human serpin A1 antibody (code A0012, dilution 1:20 000), peroxidase-conjugated swine anti-rabbit immunoglobulins (code P0217, dilution 1:3000) and peroxidase-conjugated rabbit anti-mouse immunoglobulins (code P0161, dilution 1:3000) were from DakoCytomation (Trappes, France). The monoclonal antibody ALKc (dilution 1:500) was kindly provided by Dr B Falini (Perugia, Italy).
Immunostainings. ALK1 monoclonal antibody (code M7195, dilution 1:25), CD30 monoclonal antibody (BerH2, code M0750, dilution 1:25) and the polyclonal anti-human serpin A1 antibody (code A0012, dilution 1:2000) were from DakoCytomation (Trappes, France). Immunophenotyping on cytospins of cultured cells was performed using a three-stage alkaline phosphatase technique. 18 For the 46 formalin-fixed and paraffin-embedded cases (37 ALK þ , nine ALK À ), immunostaining was performed using the streptavidin-biotin-peroxidase complex (ABC) method, as previously described. 22 For serpin A1 immunostainings, cases were considered positive when more than 10% of neoplastic cells were stained. Normal histiocytes were used as intrinsic positive controls. Statistical
Results
Confirmation of serpin A1 as a differentially expressed gene in ALCL cell lines and tumors
Our home-made ALCL-dedicated macroarray was used to analyze the gene expression profile of five ALCL cell lines (four ALK þ , one ALK À ). Among the genes differentially expressed between ALK þ and ALK À ALCL cell lines, we observed that serpin A1 was overexpressed in the ALK þ cell lines when compared to the ALK À cell line ( Figure 1A) . Northern blot and RT-qPCR gave concordant results, validating that serpin A1 was strongly overexpressed in three of the four ALK þ cell lines (SU-DHL-1, COST and PIO) when compared to the ALK À (FEPD) cell line ( Figure 1B and C) . Only the ALK þ Karpas 299 cell line, which also had the weaker level of NPM-ALK transcripts among the ALK þ cell lines, expressed low levels of serpin A1 mRNAs. A t-test, using Affymetrix microarrays data, in order to find the most significant differentially expressed genes between ALK þ ALCL and ALK À ALCL biopsies ('Class comparison') corroborated the results observed in ALCL cell lines. Indeed, among the 390 genes differentially expressed between ALK þ and ALK À cases (Pp0.001), the Serpin A1 gene was among the four top genes (excluding ALK) highly statistically discriminatory (based on the significant ranking and on a cutoff Po0.000005 by the permutation t-test). The level of serpin A1 transcripts was fivefold higher in ALK þ than in ALK À biopsies. Moreover, the 
Validation of the differential expression of serpin A1 at the protein level
To confirm the differential expression of serpin A1 at the protein level, we performed Western blot and immunostaining on ALCL cell lines and biopsy specimens using a polyclonal antibody to human serpin A1. SU-DHL-1, COST and PIO ALK þ cell lines expressed the highest level of serpin A1 protein, as assessed by immunocytochemistry and Western blot (Figure 2 ). In the Karpas 299 cell line, immunocytolabeling experiments showed a positive though heterogeneous staining, whereas the FEPD ALK À cells were all negative (Figure 2a ). Western blot analysis with an exposure time of 2 min failed to detect serpin A1 protein in Karpas 299 cells (Figure 2b) . Immunohistochemistry performed on 46 paraffin-embedded biopsies confirmed that serpin A1 was differentially expressed between ALK þ and ALK 
Modulation of NPM-ALK expression regulates serpin A1 expression
The strong expression of serpin A1 in ALK þ cell lines and tumors suggested that the NPM-ALK expression might play a role in the regulation of serpin A1. To further investigate such a hypothesis, we used the NIH3T3 cell line stably transfected with an NPM-ALK-expressing vector. The level of serpin A1 transcripts, measured by RT-qPCR, was 12 times higher in NPM-ALK-expressing cells compared to the wild-type NIH3T3 cell line (Figure 4 Aa). Western blot analysis was not performed on these cells given that anti-human serpin A1 antibody does not crossreact with murine serpin A1. The crucial role of NPM-ALK in the regulation of serpin A1 expression was further demonstrated in the human ALK þ COST cell line using the RNA interference (RNAi) technique. We controlled the specificity of the ALK siRNA duplex by analyzing the expression of the widely expressed protein b-actin by Western blotting. We observed no changes in the expression of this protein after ALK siRNA treatment ( Figure 4B ). In the ALK siRNA-treated COST cells, the downregulation of ALK expression was correlated with a proportional decrease of serpin A1 expression, observed at both the transcriptional and translational levels (Figure 4Ab and B) .
Serpin A1 expression correlates with clinical presentation in ALK þ tumors
The Affymetrix chip analysis showed that among the 24 ALK þ cases, the serpin A1 gene was overexpressed (ratio ¼ 2, P ¼ 0.048) in the 13 tumors presenting with an extranodal dissemination at diagnosis, compared to the 11 tumors involving only lymph nodes. Interestingly, in two cases showing massive sinusoidal growth pattern, serpin A1 labeling specifically highlighted the intrasinusoidal tumor cells (Figure 3b ). These patients relapsed, but no tumor biopsy was available at relapse. When material was available at diagnosis and at the time of relapse (two cases), serpin A1 immunostaining was performed at both times and revealed that only a few neoplastic CD30-positive cells were serpin A1 positive at the time of diagnosis, whereas nearly all the neoplastic cells at relapse expressed serpin A1 (Figure 3c ).
Discussion and conclusion
Serpins are thought to play a major role in cancer growth and progression, but their pro-or antitumor effects are still debated.
Depending on their class and isoform (native or cleaved), serpins can either exert a tumor-promoting or a tumor-inhibiting 
In the present study, we demonstrated the overexpression of serpin A1 in several ALK þ cell lines. We also showed, in ALCL tumors, that serpin A1 expression was clearly correlated with the presence of the ALK oncogene, both at the mRNA and protein levels. By using both ectopic expression and specific downregulation of the NPM-ALK oncogene, we showed that the serpin A1 expression followed that of NPM-ALK, further demonstrating that this oncogene was indeed regulating serpin A1 expression. Additional analysis on the precise molecular mechanism involved in this regulation is currently investigated.
Moreover, we observed that, in ALK þ tumors, the serpin A1 expression status was also correlated with extranodal dissemination in ALK þ tumors. Interestingly, neoplastic cells invading lymphatic sinuses were strongly positive for serpin A1, suggesting that they have a higher migration ability than surrounding neoplastic cells. In addition, when tumor samples were available at diagnosis and at the time of relapse, we observed at relapse a greater number of serpin A1-positive malignant cells and a stronger staining. Taken together, these findings strongly support the hypothesis of a tumor-promoting and/or invasionpromoting effect of serpin A1.
High serum levels of serpin A1 have already been associated with poor prognosis in multiple myeloma, 26 and high serpin A1 expression in tumors has been correlated with poor prognosis in different types of adenocarcinomas. [11] [12] [13] The levels of serpin A1 expression also appear to be correlated with the invasive and metastatic capacity of different tumor cells. 13, 14 . The mechanisms by which serpin A1 could have this tumor and/or invasionpromoting effect remain unclear. It has been shown by Laine et al. 27 that serpin A1 purified from the serum of healthy donors strongly inhibited the natural killer (NK) cytotoxicity in vitro. The latter finding is in keeping with previous reports showing that serpin A1 is one of most potent in vitro inhibitors of granzyme B. 28 Thus, the tumor-promoting effect of serpin A1 Interestingly, in the present study, the Karpas 299 cell line was found to express lower serpin A1 level than the COST cell line.
It has been described that tumors overexpressing SCCA1 (squamous cell carcinoma antigen), another secreted serpin, showed a higher aggressiveness, possibly owing to a diminished antitumor cytotoxic immune response. 30 Such a hypothesis was supported by the treatment of malignant cells with an SCCA siRNA that led to tumor growth inhibition in Nude mice associated with an increased number of large mononuclear infiltrating NK cells. 30 A recent proteomic analysis of ALCL cell lines has identified SCCA1 as being overexpressed in the ALK þ SU-DHL-1 cell line in comparison with the ALK À FEPD cell line. 31 Furthermore, SCCA1 was also overexpressed in the ALK þ SU-DHL-1 cell line versus the ALK þ COST cell line. Of note, SU-DHL-1 cell line was originally established from pleural effusion cells of an aggressive ALCL, which experienced repeated relapses after chemotherapy and presented with several extranodal dissemination sites. The patient died from his disease less than 6 months after diagnosis. 17 By contrast, the COST cell line was derived from the peripheral blood of a patient who achieved complete remission after chemotherapy 18 and is still in complete remission 65 months after diagnosis.
Pathogenic mechanisms leading to the resistance to cell death induced by CTL may also result in the resistance to therapy-induced cell death. Thus, serpin A1 overexpression could act in favor of tumor growth not only by protecting tumor cells from the immune response but also by protecting them from drug-induced apoptosis during chemotherapeutic treatment, as it has been demonstrated for SCCA1. 32 Indeed, in vitro experiments in epithelial models showed that SCCA1 protected cells from death induced by different proapoptotic agents or treatments. 32 In conclusion, expression of serpin A1 is strongly associated with the ALK status, further underlining the intrinsic differences between ALK þ and ALK À ALCL. Although ALK þ ALCL have a better prognosis than ALK À cases and are highly chemosensitive, in most reported studies, 20-40% of patients relapse and some of them undergo a fatal course. Furthermore, extranodal involvement at the time of diagnosis, such as cutaneous or visceral localizations, is known to be an adverse prognostic parameter. So, serpin A1 overexpression could provide a potential explanation for differences observed in the clinical outcome of ALK þ ALCL. Serpin A1 expression correlates with clinical status in ALK þ ALCL MM Duplantier et al
